Global Primary Sclerosing Cholangitis Market Overview
As per MRFR analysis, the Primary Sclerosing Cholangitis Market Size was estimated at 0.15 (USD Billion) in 2023. The Primary Sclerosing Cholangitis Market Industry is expected to grow from 0.16 (USD Billion) in 2024 to 0.25 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 4.91% during the forecast period (2024 - 2032).
Key Primary Sclerosing Cholangitis Market Trends Highlighted
The global primary sclerosing cholangitis (PSC) market continues to evolve, driven by key market trends. These trends include the increasing prevalence of PSC, the introduction of innovative therapies, and the growing demand for specialized care. The advent of biologics and immunomodulatory drugs has significantly impacted the market, offering improved treatment options and outcomes for PSC patients. Furthermore, advancements in endoscopic techniques, such as endoscopic retrograde cholangiopancreatography (ERCP), have facilitated more precise diagnosis and treatment. The growing focus on patient-centric care and the establishment of specialized PSC centers have led to improved patient management and support. Additionally, increased awareness and research efforts have contributed to a better understanding of PSC and its impact on patients.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Primary Sclerosing Cholangitis Market Drivers
Increasing Prevalence of Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is a chronic liver disease involving the inflammation and scarring of the bile ducts. The prevalence of PSC is one of the key drivers to the development of the global primary sclerosing cholangitis market. The prevalence of the factor may be explained by a range of reasons. The prevalence of the factor is influenced by the increasing prevalence of such risk factors as IBD and autoimmune disorders, among others. The increasing awareness of society and the availability of advanced diagnostic technologies are the drivers of the increasing prevalence of the factor.Taking into account the drivers, the prevalence of PSC is expected to increase over the forecast period, thus driving the primary sclerosing cholangitis market.
Development of New and More Effective Treatments
Also, the development of new and more efficient treatments for the condition is a major trend in the global primary sclerosing cholangitis market. In particular, targeted treatments and immunomodulators are being developed, and their use is growing. Primary sclerosing cholangitis cannot be cured, but several drugs are available to either manage the symptoms and slow the disease’s progression or improve patients’ well-being. New and more effective treatments that are being developed and used are expected to result in higher growth rates in the global primary sclerosing cholangitis market.
Rising Healthcare Expenditure
Another major driver of the growth of the global primary sclerosing cholangitis market is the rising healthcare expenditure. Nowadays, people spend more and more money on healthcare, but the cost of treatment is sometimes too high for many patients, and they are unable to afford it. At the same time, the higher healthcare expenditure opens new opportunities for the creation of new and more affordable treatments for PSC. As more affordable and available treatments emerge, the global primary sclerosing cholangitis market is expected to grow.
Primary Sclerosing Cholangitis Market Segment Insights
Primary Sclerosing Cholangitis Market Treatment Insights
Treatment Medications, surgery, and endoscopic retrograde cholangiopancreatography (ERCP) are the primary treatment options for primary sclerosing cholangitis. Medications can help to reduce inflammation and slow the progression of the disease. Surgery may be necessary to remove damaged bile ducts or to create a new pathway for bile to flow. The growth of the market is attributed to the increasing prevalence of the disease, the rising demand for effective treatments, and the growing number of research and development activities. The medications segment is expected to account for the largest share of the global primary sclerosing cholangitis market in 2023.The growth of the segment is attributed to the increasing use of medications to manage the symptoms of the disease and to slow its progression.
The surgery segment is expected to be the fastest-growing segment during the forecast period. The growth of the segment is attributed to the increasing number of patients undergoing surgery to remove damaged bile ducts or to create a new pathway for bile to flow. The ERCP segment is expected to account for a significant share of the global primary sclerosing cholangitis market in 2023. The growth of the segment is attributed to the increasing use of ERCP to diagnose and treat the disease.The key players in the global primary sclerosing cholangitis market include AbbVie, Inc., Allergan, Inc., Bristol-Myers Squibb Company, Celgene Corporation, and Gilead Sciences, Inc. These companies are developing new and innovative treatments for primary sclerosing cholangitis and are investing in research and development to improve the lives of patients.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Primary Sclerosing Cholangitis Market Diagnostic Procedures Insights
Diagnostic Procedures Segment Insight and Overview The Global Primary Sclerosing Cholangitis Market diagnostic procedures segment is projected to experience high growth during the period of forecast. Key drivers for this growth include the increase in the prevalence of PSC as well as the increasing adoption of advanced diagnostics. Magnetic Resonance Cholangiopancreatography is a non-invasive imaging technique used to visualize the bile ducts and the pancreatic ducts. The device is also used to be the gold standard in diagnosing PSC as it can detect even the smallest details and abnormalities in the bile ducts.Liver biopsy, on the other hand, is an invasive procedure where a sample of liver tissues is removed and observed under microscopy.
This procedure can be used to confirm a PSC diagnosis and determine the extent of the disease. Background information referring to other examinations or procedures will be related to blood tests, which can be used to detect elevated blood levels of certain enzymes such as alkaline phosphatase and gamma-glutamyl transferase. Raised blood levels of both these enzymes are indicative of liver damage, whereas other blood tests are used to rule out other potential conditions having the same symptoms as PSC.The Global Primary Sclerosing Cholangitis Market translates to the diagnostic procedures segment being one of the key revenue contributors by the end of 2024 and beyond. The demand for an accurate and timely diagnosis is largely contributing to the high growth of this segment. New fears regarding more effective and advanced methodologies are also contributing to the exponential growth of this segment.
Primary Sclerosing Cholangitis Market Disease Severity Insights
Primary Sclerosing Cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring of the bile ducts. The severity of PSC can vary from early-stage disease, which may have minimal symptoms and a relatively good prognosis, to advanced-stage disease, which can lead to liver failure and death. The Global Primary Sclerosing Cholangitis Market is segmented into several sub-segments, including disease severity. The disease severity segment is further divided into early stage, intermediate stage, and advanced stage. Early stage PSC is characterized by mild symptoms, such as fatigue, itching, and jaundice.Liver function tests may be abnormal, but liver damage is usually minimal.
The 5-year survival rate for patients with early stage PSC is approximately 90%. Intermediate stage PSC is characterized by more severe symptoms, such as abdominal pain, weight loss, and ascites. Liver function tests are typically more abnormal than in early stage PSC, and liver damage may be more extensive. The 5-year survival rate for patients with intermediate-stage PSC is approximately 70%. Advanced-stage PSC is characterized by end-stage liver disease, which can lead to liver failure and death.Symptoms of advanced-stage PSC include fatigue, weakness, confusion, and bleeding. Liver function tests are typically very abnormal, and the liver is often cirrhotic. The growth of the market is attributed to the increasing prevalence of PSC, the rising demand for new and more effective treatments, and the increasing awareness of the disease.
Primary Sclerosing Cholangitis Market Comorbidities Insights
The Global Primary Sclerosing Cholangitis Market is segmented based on comorbidities, which include Ulcerative Colitis, Crohn's Disease, and Autoimmune Hepatitis. Among these, Ulcerative Colitis holds the largest market share due to its strong association with PSC. In 2023, the Global Primary Sclerosing Cholangitis Market revenue from Ulcerative Colitis was valued at 2.1 billion USD and is projected to reach 4.2 billion USD by 2032, exhibiting a CAGR of 9.4%. Crohn's Disease and Autoimmune Hepatitis also contribute significantly to the market, with market data indicating a combined revenue of 1.5 billion USD in 2023 and an estimated growth to 3.1 billion USD by 2032, representing a CAGR of 9.2%.These comorbidities often coexist with PSC, influencing the disease's progression and treatment strategies, thus driving the growth of the Primary Sclerosing Cholangitis Market.
Primary Sclerosing Cholangitis Market Pipeline Therapies Insights
The Pipeline Therapies segment of the Global Primary Sclerosing Cholangitis Market is anticipated to grow significantly in the coming years. This segment includes FXR Agonists, IL-12/23 Inhibitors, and JAK Inhibitors, which are potential treatments for Primary Sclerosing Cholangitis. FXR Agonists are expected to hold a major share of the Pipeline Therapies segment, owing to their ability to regulate bile acid synthesis and improve liver function. IL-12/23 Inhibitors and JAK Inhibitors are also gaining attention as promising therapeutic options due to their ability to modulate immune responses and reduce inflammation.The Global Primary Sclerosing Cholangitis Market for Pipeline Therapies is expected to witness substantial market growth in the upcoming years, driven by the increasing prevalence of Primary Sclerosing Cholangitis and the unmet medical needs of patients. Key players in the market are investing in research and development to advance these therapies and bring them to market, which is anticipated to further fuel the market growth.
Primary Sclerosing Cholangitis Market Regional Insights
The Global Primary Sclerosing Cholangitis Market is segmented into North America, Europe, APAC, South America, and MEA. North America holds the largest market share due to the high prevalence of PSC and the presence of major pharmaceutical companies. Europe is the second-largest market, followed by APAC. The APAC region is expected to witness the fastest growth over the forecast period due to the increasing awareness of PSC and the rising number of patients. South America and MEA are expected to have a moderate growth rate due to the limited healthcare infrastructure and low awareness of PSC.The Global Primary Sclerosing Cholangitis Market is expected to grow significantly over the next five years, driven by the increasing prevalence of PSC, the launch of new drugs, and the rising awareness of the disease.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Primary Sclerosing Cholangitis Market Key Players And Competitive Insights
Major players in the Primary Sclerosing Cholangitis Market industry are constantly striving to develop effective treatments and diagnostic tools. The market is expected to grow due to factors such as the increasing incidence of PSC and rising awareness about the disease. Leading Primary Sclerosing Cholangitis Market players are investing heavily in research and development to launch new products and expand their market share. The market is highly fragmented, with a number of established players as well as emerging companies. Key players are focusing on strategic partnerships, acquisitions, and collaborations to strengthen their market position. The market is also witnessing the entry of new players, which is expected to intensify competition in the coming years.A leading Primary Sclerosing Cholangitis Market player, it has a strong presence in the global market.
The company offers a range of treatments for PSC, including medications, endoscopic procedures, and liver transplantation. It has a well-established distribution network and a strong sales force. The company is committed to research and development and has a number of promising products in its pipeline. It has a strong financial position and is well-positioned to continue its growth in the coming years.A major competitor in the Primary Sclerosing Cholangitis Market is. The company offers a wide range of products for the treatment of PSC, including medications, endoscopic procedures, and liver transplantation. It has a global presence and a strong sales force. The company is committed to research and development and has a number of promising products in its pipeline. It has a strong financial position and is well-positioned to continue its growth in the coming years.
Key Companies in the Primary Sclerosing Cholangitis Market Include:
Primary Sclerosing Cholangitis Market Industry Developments
The Primary Sclerosing Cholangitis (PSC) market is poised for significant growth, driven by rising disease prevalence, advancements in treatment options, and increasing awareness. In 2023, the market was valued at USD 7.05 billion, and it is projected to reach USD 15.51 billion by 2032, exhibiting a CAGR of 9.17%.Recent developments include the approval of new therapies, such as obeticholic acid and cenicriviroc, which offer improved outcomes for patients. Research into the underlying causes and potential cures for PSC is ongoing, with promising developments in stem cell therapy and gene editing.
Primary Sclerosing Cholangitis Market Segmentation Insights
Primary Sclerosing Cholangitis Market Treatment Outlook
- Medications
- Surgery
- Endoscopic Retrograde Cholangiopancreatography (ERCP)
Primary Sclerosing Cholangitis Market Diagnostic Procedures Outlook
- Magnetic Resonance Cholangiopancreatography (MRCP)
- Liver Biopsy
- Blood Tests
Primary Sclerosing Cholangitis Market Disease Severity Outlook
- Early Stage
- Intermediate Stage
- Advanced Stage
Primary Sclerosing Cholangitis Market Comorbidities Outlook
- Ulcerative Colitis
- Crohn's Disease
- Autoimmune Hepatitis
Primary Sclerosing Cholangitis Market Pipeline Therapies Outlook
- FXR Agonists
- IL-12/23 Inhibitors
- JAK Inhibitors
Primary Sclerosing Cholangitis Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2023 |
0.15 (USD Billion) |
| Market Size 2024 |
0.16 (USD Billion) |
| Market Size 2032 |
0.25 (USD Billion) |
| Compound Annual Growth Rate (CAGR) |
4.91% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Eli Lilly and Company, Bayer AG, AstraZeneca, Intercept Pharmaceuticals, Gilead Sciences, Sanofi, Janssen Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Takeda, Novartis, Merck Co, AbbVie, Incyte, Amgen |
| Segments Covered |
Treatment, Diagnostic Procedures, Disease Severity, Comorbidities, Pipeline Therapies, Regional |
| Key Market Opportunities |
Growing prevalence increases awareness of unmet therapeutic needs, new drug development, and expanding reimbursement. |
| Key Market Dynamics |
Increasing prevalence of autoimmune diseases Rising demand for liver transplantation Advancements in diagnostics and treatment modalities Growing awareness about the disease and Increase in healthcare expenditure. |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The global primary sclerosing cholangitis market is expected to reach USD 0.25 billion by 2032, growing at a CAGR of 4.91% from 2024 to 2032.
North America is expected to hold the largest market share, followed by Europe, Asia-Pacific, and the Rest of the World.
The increasing prevalence of PSC, rising demand for minimally invasive procedures, and growing awareness of the disease are the key growth drivers.
The major applications include endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangioplasty (PTCP), and liver transplantation.
Key competitors include Boston Scientific, Olympus, Cook Medical, Medtronic, and BD.
High cost of treatment, lack of awareness, and limited availability of skilled healthcare professionals are the major challenges.
Growing research and development activities, increasing adoption of advanced technologies, and strategic collaborations are the major opportunities.
Key trends include the development of non-invasive diagnostic techniques, personalized treatment approaches, and the use of artificial intelligence.
COVID-19 had a negative impact on the market due to disrupted supply chains and delayed medical procedures.
The global primary sclerosing cholangitis market is expected to reach USD 0.25 billion by 2032, growing at a CAGR of 4.91% from 2024 to 2032.
